[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apol1-associated-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apol1-associated-kidney-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100489679","apol1-genetic-testing-in-african-americans-100489679",false,"NCT05656261","APOL1 Genetic Testing in African Americans","APOL1 Genetic Testing in African Americans: Exploring Attitudes About Genetic Risk to Improve Comprehensive Kidney Risk Assessment for Patients and Families","Inclusion Criteria:\n\n* Ages 18-90\n* Self-Identified as Black\u002FAfrican American. Race will be self-identified. Patients of African ancestry who identify as multi-racial are also eligible to participate.\n\nExclusion Criteria:\n\n* Cognitively impaired\u002Funable to provide consent\n* Terminally ill\n* Renal replacement therapy (RRT), e.g., (but not limited to) hemodialysis, peritoneal dialysis",true,"ALL","18 Years","90 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient perceptions about knowledge of the results of APOL1 genetic testing, and how that impacts patient engagement with management of hypertension and other renal risk factors, is urgently needed.\n\n* In a Phase 1 pilot study, we offered APOL1 genetic testing to Black patients seen in our Hypertension and Nephrology clinics at Saint Louis University, an academic medical center that serves the local urban community, and surveyed patients on attitudes and concerns about APOL1 genetic testing. 144 participants were enrolled in Phase 1.\n* In the Phase 2 study, we will advance this important work in our community by offering participation to a broader patient base, including patients seen in Internal and Family Medicine clinics, SLU Hospital, as well as to first-degree relatives and spouses of SLUCare participants. This expansion seeks to advance understanding of environment-gene interactions, improve risk prediction, and target management of potentially modifiable risk factors.",[26,27,28,29,30],"Genetic Predisposition","Chronic Kidney Diseases","Nephropathy","APOL1 Associated Kidney Disease","Disparities",[32],"APOL1 Renal Risk Variants","RECRUITING","2025-03-17",{"date":36,"type":37},"2025-03-20","ACTUAL",{"date":39,"type":37},"2019-01-24",{"date":41,"type":22},"2027-06-30",{"name":43,"class":44},"St. Louis University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100550127","predictive-determinants-of-nephrotic-syndrome-remission-in-patients-with-at-risk-polymorphism-of-apol1-100550127","NCT06443034","Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene","NEPHROL1","Inclusion Criteria:\n\n* Adult patients followed in 6 nephrology centers between 01\u002F01\u002F2016 and 01\u002F06\u002F2024.\n* With characterization of APOL1 gene risk status\n* Proteinuria\u002Fcreatinuria ratio \\> 3 g\u002Fg at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)\n* Hypoalbuminemia \\\u003C 30 g\u002FL at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)\n* Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.\n\nExclusion Criteria:\n\n* Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study\n* Presence of endo- or extracapillary hypercellular lesions on light microscopy\n* Opposition to the use of medical data",{"count":55,"type":22},124,"This is a multicentric retrospective observational cohort study.\n\nAs primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.\n\nAs secondary objectives, this study aims:\n\n* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome\n* To identify the predictors of complete renal remission of nephrotic syndrome\n* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease\n* To assess the adverse events of corticosteroids in patients treated with corticosteroids.",[58,59,29],"Nephrotic Syndrome","Focal Segmental Glomerulosclerosis",[61,62,63,64,65,66],"Nephrotic syndrome","Covid-19 associated nephropathy","human immunodeficiency virus associated nephropathy","APOL1 associated kidney disease","Focal segmental glomerulosclerosis","Minimal change disease","NOT_YET_RECRUITING","2024-06-03",{"date":70,"type":37},"2024-06-05",{"date":72,"type":22},"2024-06-30",{"date":74,"type":22},"2024-12-30",{"name":76,"class":44},"Assistance Publique - Hôpitaux de Paris"]